Jul. 4 at 4:28 AM
$TNYA smart money been quietly setting up for h2 2026 all year and nobody talking about it
look at who’s in the name. millennium added 18% into sub-
$1 tape. renaissance +101%. citadel sitting tight. marshall wace +92%. these are the quant desks that know how to read a delayed catalyst setup. traditional long-only funds gone, quants/passive/PIPE = ~90% of the register now. the setup is done.
alnylam just paid
$10M upfront + up to
$1.13B biobucks in march for tenaya’s target ID engine.
$42B mcap cardiac pharma doesnt sign a deal like that unless they see something. brought in mark wine as new CFO from astellas/biogen bd background. thats not a bookkeeper hire, thats a deal structurer hire, positioned 6mo before data.
may 15 ridge-1 print already showed 64% mean PVC reduction, one patient went from 78 NSVTs/day to zero. tape faded from
$1 to $.77 because delayed recognition + warrant overhang from dec 2025 offering. thats the setup. good data + no follow through = accumulation window.
whats coming h2 2026 that nobody pricing in:
• tn-201 mypeak-1 2yr cohort 1 durability
• tn-201 cohort 2 (higher 6E13 dose) 1yr readout
• tn-401 ridge-1 2yr cohort 1 durability
• tn-401 cohort 2 higher dose readout
• regulatory alignment on BOTH pivotal designs by year-end
thats 5 discrete binary catalysts in a 4 month window. analyst medians walked down to
$3.06 median, low
$2.02 = even bear case is 2.5x from here. simply wall st has them at
$121M profit by 2028. no debt,
$100M+ cash, 15mo runway which gets them past readouts.
comps for approved cardiac gene therapy: krys
$11B, qure
$3-4B, rckt
$2-3B pre-fade.
$4B mcap in 2 years is base case if durability holds and 1 pivotal aligns.
the tape is coiled, quants accumulating, catalysts dated, warrant overhang exhausted, partner validated. this is what pre-catalyst positioning looks like. everyone will be talking about it in october. right now its still quiet.
im long, HODL through the readouts. nfa, Do your own DD.
